TargetMol

Miltefosine

Product Code:
 
TAR-T0033
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0033-50mg50mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0033-100mg100mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0033-200mg200mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0033-500mg500mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Miltefosine is the treatment of visceral and cutaneous leishmaniasis drug , and is proceeding clinical trials for this in several countries. Several medical agents produce some potency against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis.
CAS:
58066-85-6
Formula:
C21H46NO4P
Molecular Weight:
407.576
Pathway:
Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Microbiology/Virology; Chromatin/Epigenetic; Proteases/Proteasome
Purity:
0.9951
SMILES:
CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
Target:
Akt; HIV Protease; PKC

References

1. Uberall F, et al. Y Res, 1991, 51(3), 807-812. 2. Chugh P, et al. Retrovirology, 2008, 5, 11. 3. Ruiter GA, et al. Anticancer Drugs, 2003, 14(2), 167-173.